[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620473":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":24,"responsibleParty":66,"collaborators":10,"id":68,"slug":10,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":10,"enrollmentInfo":77,"targetDuration":10,"studyType":80,"phases":10,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with ATTR-CM",null,"Patients with ATTR-CM.",[13],{"name":14,"affiliation":5,"role":15},"Medical Director","STUDY_DIRECTOR",[17,22],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":18,"role":19,"phone":23,"phoneExt":10,"email":21},"1-877-256-9526",[25,39,48,57],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":10},"Clinical Trial Site","RECRUITING","Naples","Florida","34102","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-81.79596,26.14234,{"lat":37,"lon":36},{"facility":26,"status":27,"city":40,"state":41,"zip":42,"country":31,"countryCode":32,"cosmosGeoPoint":43,"geoPoint":47,"contacts":10},"Boston","Massachusetts","02215",{"type":34,"coordinates":44},[45,46],-71.05977,42.35843,{"lat":46,"lon":45},{"facility":26,"status":27,"city":49,"state":50,"zip":51,"country":31,"countryCode":32,"cosmosGeoPoint":52,"geoPoint":56,"contacts":10},"New Brunswick","New Jersey","08901",{"type":34,"coordinates":53},[54,55],-74.45182,40.48622,{"lat":55,"lon":54},{"facility":26,"status":27,"city":58,"state":59,"zip":60,"country":31,"countryCode":32,"cosmosGeoPoint":61,"geoPoint":65,"contacts":10},"Memphis","Tennessee","38120",{"type":34,"coordinates":62},[63,64],-90.04898,35.14953,{"lat":64,"lon":63},{"type":67,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100620473",false,"NCT07358078","DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting","DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting","DemonsTTRate","Inclusion Criteria:\n\n* Has a diagnosis of ATTR-CM\n* Is initiating treatment with vutrisiran or another approved ATTR-CM therapy\n\nExclusion Criteria:\n\n* Is enrolled in an interventional clinical trial","ALL","18 Years",{"count":78,"type":79},2000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to:\n\n* Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care\n* Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care\n* Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care\n* Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care",[83],"Transthyretin Amyloidosis With Cardiomyopathy",[85,86,87,88,89],"ATTR-CM","Transthyretin","Amyloidosis","ATTR","Cardiomyopathy","2026-04-23",{"date":92,"type":93},"2026-04-24","ACTUAL",{"date":95,"type":93},"2026-01-09",{"date":97,"type":79},"2030-10-23",{"name":5,"class":6},4]